Depression and treatment with anti‐calcitonin gene related peptide (<scp>CGRP)</scp> (ligand or receptor) antibodies for migraine

Abstract

Anti-CGRP (ligand or receptor) monoclonals lead to improvement of depressive symptoms in individuals with migraine, independent of migraine reduction. Depression may predict treatment response to erenumab but not to fremanezumab.